13 AUG 2002p

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Ap	pplication of:)
Liang e	t al.)) Art Unit: Not Vot Assigned
Serial N	o. 10/070,560) Art Unit: Not Yet Assigned) Description Not Yet Assigned
Filed:	March 8, 2002) Examiner: Not Yet Assigned)
For:	Method of Producing and Purifying Endostatin Protein))

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, DC 20231

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

This Supplemental Information Disclosure Statement is being filed before the mailing of the first Office Action on the merits (37 C.F.R. 1.97(b)(3)); therefore, no fee is believed to be required. However, if a first Office Action on the merits has issued, please consider this Information Disclosure Statement under 37 C.F.R. 1.97(c). The Commissioner is hereby authorized to charge the applicable fees, if any, to Deposit Account No. 11-0855.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on <u>August 08, 2002</u>

ATLLIB02 86774.1

Idmie I. Greene - Reg. No. 32 46

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Vamie L. Greene Reg. No. 32,467

KILPATRICK STOCKTON LLP 1100 Peachtree Street, Suite 2800 Atlanta, Georgia 30309-4530 (404) 815-6500

Our Docket: 05213-0551US (43170-258385)

PTO/SB/08A (08-00)

Approved for U.S. Patent and Trademark Office brough 10/31/2002 OMB 0651-0031 DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, it is a relative to respond to a collection of information unless a control number

Substitute for Form 1449/A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

7

of

Complete if Known				
Application No.	10/070,560			
Filing Date	03/08/2002			
First Named Inventor	Liang et al.			
Group Art Unit	Not Yet Assigned			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	05213-0551US (43170-258385)			

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.1	U.S. Patent Document Kind C Number ⁴ (if kno	1141110 01 1 41011100 01	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1	60/80728	MIXSON, James A.	06/27/2000		

Examiner	Date	
Signature	Considered	

Approved for use through 10/31/2002 OMB 0651-0031

U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark respond to a collection of informa less it contains a valid OMB control number Under the Paperwork Reduction Act of Complete if Known Application No. 10/070,560 Substitute for Form 1449/A/PTO 03/08/2002 Filing Date INFORMATION DISCLOSURE First Named Inventor Liang et al. STATEMENT BY APPLICE Group Art Unit Not Yet Assigned (use as many sheets as necessary) **Examiner Name** Not Yet Assigned Attorney Docket Number 05213-0551US (43170-258385) Sheet 2 of 7 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite T۴ item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials No. publisher, city and/or country where published Author: Title: Chapter 12: Vectors for Gene Therapy 2 Publ: Current Protocols in Human Genetics Vol/Iss: Pages: Date: 1997 Title: A versatile vector for gene and oligonucleotide transfer into cells in culture andin Author: BOUSSIF, O. et al. vivo: Polyethylenimine Publ: Proc. Natl. Acad. Sci. USA Vol/Iss: 92 Pages: 7297-7301 Date: 08/1995 Author: CALOS, MICHELE P. Title: The potential of extrachromosomal replicating vectors for gene therapy Publ: TIG Vol/lss: 12 (11) Pages: 463-466 Date: 11/1996 Author: CHEN, P. et al. Title: Genetic Mechanisms of Tumor Suppression by the Human p53 Gene Publ: <u>Science</u> Pages: 1576-1579 Date: 12/1990 Vol/Iss: 250 Title: Receptor Ligand-Facilitated Gene Transfer: Enhancement of Liposome-Mediated Gene Author: CHENG, PI-WAN Transfer and Expression by Transferrin Publ: Human Gene Therapy Vol/iss: 7 Pages: 275-282 Date: 02/10/199 Title: The 16-kilodalton N-terminal Fragment Of Human Prolactin Is A Potent Inhibitor Of Author: CLAPP, C. et al. Angiogenesis Publ: Endocrinology Pages: 1292-1299 Date: 03/01/93 Vol/Iss: 133 Title: Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1 Author: DAMERON, K.M. et al.

Examiner	Date	
Signature	Considered	

Vol/Iss: 265

Pages: 1582-1584

Date: 09/09/94

Publ: Science

U.S. Patent and Trademarl ersons are quired to respond to a collection of informa

e: U.S. DEPARTMENT OF COMMERCE less it contains a valid OMB control number

Under the Paperwork Reduction Act of Complete if Known Application No. 10/070,560 Substitute for Form 1449/A/PTO Filing Date 03/08/2002 INFORMATION DIS First Named Inventor Liang et al. STATEMENT BY APP Group Art Unit Not Yet Assigned (use as many sheets as necessary) **Examiner Name** Not Yet Assigned 05213-0551US (43170-258385) Sheet 3 of 7 Attorney Docket Number OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite T item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials No. publisher, city and/or country where published Title: The structure of endothelial cell thrombospondin - Characterization of the Author: DARDIK, R. et al heparin-binding domains Publ: Date: 10/15/198 Eur J Biochem Vol/lss: 168 (2) Pages: 347-355 Title: Regulation of Gene Expression in Vivo by Liposome-mediated Delivery of a Purified Author: DEBS, R.J. et al. 10 **Transcription Factor** Publ: The Journal of Biological Chemistry Pages: 10189-10192 Date: 06/25/199 Vol/lss: 265 (18) Author: DIXIT, V.M. et al. Title: A monoclonal antibody against human thrombospondin inhibits platelet aggregation 11 Publ: Proc. Natl. Acad. Sci. USA Vol/Iss: 82 Pages: 3472-3476 Date: 05/1985 12 Author: FAN et al. Title: Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy Publ: Trends in Pharmacolgical Sciences Vol/Iss: 16(2) Pages: 57-66 Date: 02/95 Title: The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis Author: FIDLER et al. Publ: <u>Cell</u> Date: 10/21/94 Vol/lss: 79(2) Pages: 185-188 Title: Induction of Chemosensitivity in Human Lung Caner Cells in Vivo by Author: FUJIWARA, T. et al. 14 Adenovirus-mediated Transfer of the Wild-Type p53 Gene Publ: Cancer Research Vol/Iss: 54 Pages: 2287-2291 Date: 05/01/199 Title: In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer Author: GOLDMAN, C.K. et al. Publ: Nature Biotechnology Vol/Iss: 15 Pages: 462-466 Date: 05/1997

Examiner	Date	
Signature	Considered	

U.S. Patent and Trademar

e: U.S. DEPARTMENT OF COMMERCE less it contains a valid OMB control number

rsons are required to respond to a collection of information Under the Paperwork Reduction Act of Complete if Known Application No. 10/070,560 Substitute for Form 1449/A/PTO 03/08/2002 Filing Date INFORMATION DIS First Named Inventor Liang et al. STATEMENT BY APPE Group Art Unit Not Yet Assigned (use as many sheets as necessary) **Examiner Name** Not Yet Assigned Attorney Docket Number 05213-0551US (43170-258385) Sheet 4 of 7 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite T۴ item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials No. publisher, city and/or country where published Title: Clinical trials of antiangiogenic agents Author: HAWKINS, MICHAEL J, 16 M.D. Publ: Current Opinion in Oncology Vol/iss: 7 Pages: 90-93 Date: 1995 Title: Novel Cancer Approach From Noted Scientist Hits Stumbling Block Author: KING, RALPH P. Jr. Publ: Wall Street Journal Vol/Iss: Pages: A1, A8 Date: 11/12/199 Title: Identification of a New Cell Adhesion Motif in Two Homologous Peptides from the Author: KOSFELD, M.D. et al. 18 COOH-terminal Cell Binding Domain on Human Thrombospondin Publ: The Journal of Biological Chemistry Vol/Iss: 268 (12) Pages: 8808-8814 Date: 1993 Title: Systemic Gene Therapy with p53 Reduces Growth and Metastases of a Malignant 19 Author: LESOON-WOOD, L.A. et al. Human Breast Tumor in Nude Mice Publ: Human Gene Therapy Vol/Iss: 6 Pages: 395-405 Date: 04/1995 Title: Inhibition of Tumor Growth in Mice by an Analogue of Platelet Factor 4 That Lacks Author: MAIONE, T.E. et al. Affinity for Heparin and Retains Potent Angiostatic Activity Publ: Cancer Research Vol/Iss: 51 Pages: 2077-2083 Date: 04/15/199 Author: MARSHALL, ELIOT Title: Gene Therapy's Growing Pains Publ: Date: 08/25/199 <u>Science</u> Vol/lss: 269 Pages: 1050-1055 Author: MILLAUER, B. et al. Title: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant Publ: Nature Vol/Iss: 367 Pages: 576-579 Date: 02/10/94

Examiner	Date	
Signature	 Considered	

^{&#}x27;Unique citation designation number. ¹See attached Kinds of U.S. Patent Documents. ¹Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language translation is attached.

U.S. Patent and Trademark

E: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of gired to respond to a collection of informa less it contains a valid OMB control number Complete if Known Substitute for Form 1449/A/PTO Application No. 10/070,560 Filing Date 03/08/2002 INFORMATION DISCLOS First Named Inventor Liang et al. STATEMENT BY APP Group Art Unit Not Yet Assigned (use as many sheets as necessary) Not Yet Assigned **Examiner Name** Sheet 5 of 7 Attorney Docket Number 05213-0551US (43170-258385) OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite T۴ item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials publisher, city and/or country where published Title: Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of 23 Author: O'REILLY et al. Metastases by a Lewis Lung Carcinoma Publ: Cell Vol/Iss: 79 Pages: 315-328 Date: 10/21/94 Author: O'REILLY et al. Title: Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth Publ: Cell Vol/lss: 88 Pages: 277-285 Date: 01/24/97 Title: Development of liposome- and anti-HER2 immunoliposomeplasmid complexes for 25 Author: PARK et al. efficient and selective gene therapy Publ: Proceedings of the American Association for Cancer Research Vol/Iss: 38 Pages: 342 Date: 03/1997 Author: PASQUALINI, R. et al. Title: αv Integrins as recptors for tumor targeting by circulating ligands Publ: Nature Biotechnology Vol/iss: 15 Date: 06/1997 Pages: 542-546 Author: PASQUALINI, R. et al. Title: Organ targeting in vivo using phage display peptide libraries Publ: Date: 03/28/199 Nature 1 4 1 Vol/Iss: 380 Pages: 364-166 Title: Inhibition of Tumor Ahgiogenesis by a Synthetic Cell-adhesive Polypeptide Containing Author: SAIKI et al. 28 the Arg-Gly-Asp (RGD) Sequence of Fibronectin, Poly(RGD) Publ: Jpn. J. Cancer Research Vol/iss: 81 Pages: 668-675 Date: 1990 Author: SAKAMOTO, N. et al. Title: Inhibition of Angiogenesis And Tumor Growth By A Synthetic Laminin Peptide. Cdpgyigsr-nh2

Examiner	Date	
Signature	Considered	
-		

Vol/Iss: 51

Pages: 903-906

Date: 02/01/91

Cancer Research

T

1998

Date:

U.S. Patent and Trademar

e: U.S. DEPARTMENT OF COMMERCE less it contains a valid OMB control number

Under the Paperwork Reduction Act of

Sheet

Examiner

Initials

Cite

30

31

aired to respond to a collection of information

Substitute for Form 1449/A/PTO INFORMATION DISC STATEMENT BY API

6

(use as many sheets as necessary)

7

of

Author: TANAKA, T. et al.

Molecular Genetics and Metabolism

Complete if Known 10/070,560 Application No. Filing Date 03/08/2002 First Named Inventor Liang et al. Group Art Unit Not Yet Assigned **Examiner Name** Not Yet Assigned 05213-0551US (43170-258385) Attorney Docket Number

Pages: 001-005

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),

Title: Overexpression of p21WAF1/CIP1 induces frowth arrest, giant cell formation and Author: SHEIKH et al. apoptosis in human breast carcinome cell lines Publ:

publisher, city and/or country where published

Oncogene Vol/Iss: 11 Pages: 1899-1905 Date: 1995

angiogenesis and tumor growth Publ: Nature Medicine Vol/Iss: 3 Pages: 437-442 Date: 04/1997

Title: Viral vector-mediated transductions of a modified platelet factor 3 cDNA inhibits

Title: Peptides Derived From Two Separate Domains Of The Matrix Protein 32 Author: TOLSMA, S.S. et al. Thrombospondin-1 Have Antiangiogenic Activity Publ: Journal of Cell Biology Vol/lss: 122 Pages: 497-511 Date: 07/1993

Author: WEINSTAT-SASLOW, D.L. Title: Transfection of Thrombospondin 1 Complementary DNA into a Human Breast Carcinoma Cell Line Reduces Primary Tumor Growth, Metastatic Potential, and Publ: <u>Anniannenecie</u> Cancer Research Vol/lss: 54 Pages: 6504-6511 Date:

Author: XU, M. et al. Title: In Vivo Gene Therapy with a Cationic Polymer Markedly Enhances the Antitumor Activity of Antiangiogenic Genes Publ:

Title: Gene Therapy with P53 and a Fragment of Thrombospondin I Inhibits Human Breat Author: XU, M. et al. 35 Cancer in Vivo Publ:

Pages: 103-109 Molecular Genetics and Metabolism 1998 Vol/Iss: 63 Date: Title: Parenteral Gene Therapy with p53 Inhibits Human Breat Tumors In Vivo Through a 36 Author: XU, M. et al. Bystander Mechanism Without Evidence of Toxicity

Vol/Iss: 64

Pages: 177-185 Date: 01/20/199 Human Gene Therapy Vol/Iss: 8

Examiner	Date		
Signature	Considered	1	

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademari Cee: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of the Paperwork Reduction Act

Substitute for Form 1449/A/PTO AUG 1 3 2002		Compl	ete if Known		
		n 1449/A/PTO uig 1 3 2002	Application No.	10/070,560	
		\	Filing Date	03/08/2002	
INFORMATION DISCLOSUSE			First Named Inventor	Liang et al.	
S	TA	TEMENT BY APPERCANT	Group Art Unit	Not Yet Assigned	
		(use as many sheets as necessary)	Examiner Name	Not Yet Assigned	
Sheet		7 of 7	Attorney Docket Number	05213-0551US (43170-258385)	
		<u> </u>			
		OTHER PRIOR ART - NON PA	TENT LITERATURE DOCI	IMENTS	
	T	Include name of the author (in CAPITAI		· · · · · · · · · · · · · · · · · · ·	
Examiner Initials	Cite No.1	item (book, magazine, journal, serial, syr	posium, catalog, etc.), date, page(s), volume-issue number(s),		
	110.	publisher, ci	ty and/or country where published		
	37	Author: ZABRENETZKY, V. et al. Title: EXPRESSION OF THE EXTRACELLULAR MATRIX MOLECULE			
		1	MBOSPONDIN INVERSELY CORRE		
	İ	Int. J. Cancer	Vol/lss: 59 Pag	ges: 191-195 Date: 1994	
	38	Author: ZHU, N. et l. Title: System	nic Gene Expression After Intravenous D	ONA Delivery into Adult Mice	
		 Publ:			
		<u>Science</u>	Vol/Iss: 261 Pag	ges: 209-211 Date: 07/09/199	
1	I				

Examiner	Date	
Signature	Considered	